Recombinant ITGA5 (Volociximab Biosimilar) antibody

Catalog No. ABIN5668270

The Human Monoclonal anti-ITGA5 (Volociximab Biosimilar) antibody (Clone M200) (ABIN5668270) specifically detects ITGA5 (Volociximab Biosimilar) in FACS, BR, ELISA, IF, IHC (p) and IHC (fro). The antibody is reactive with Human samples.

Quick Overview for Recombinant ITGA5 (Volociximab Biosimilar) antibody (ABIN5668270)

Target: ITGA5 (Volociximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Flow Cytometry (FACS), Blocking Reagent (BR), ELISA, Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: M200

Product Details

Purpose: Anti-alpha 5 beta 1 Integrin [M200 (Volociximab)], Human IgG4, kappa

Specificity:

This antibody is specific for human α5β1 integrin. Cross-reactivity studies revealed no binding to other human integrins such as α3β1, αvβ3, or αvβ5. It does, however, bind to α5β1 in the vasculature of cynomolgus monkeys, but not in mice. α5β1 is part of the integrin superfamily-glycoprotein transmembrane receptors that interact with ligands such as fibronectin, vitronectin, laminins, and collagens. This receptor plays a key role in processes including inflammation, cell proliferation, angiogenesis, and tumor metastasis.

Application Notes original Clone: This antibody binds human α5β1 integrin with high affinity (Kd = 0.367 nM, EC₅₀ = 0.2 nM, IC₅₀ = 2.3 nM) and, in chimeric mouse-human IgG4 form, demonstrated potent anti angiogenic and anti tumor effects in preclinical models (laser induced CNV in cynomolgus monkeys, VX2 carcinoma in rabbits) before progressing into Phase II trials in platinum resistant ovarian cancer (Ramakrishnan et al., 2006, PMID: 17024968, Bhaskar et al., 2007, PMID: 17786386). Exclusive binding to α5β1 (no cross reactivity with α3β1, αvβ3, αvβ5) was confirmed by ELISA. Immunohistochemistry (IHC-F) demonstrated binding to cynomolgus vasculature but not to mouse tissue. Studies with recombinant integrin subunits revealed that binding depends specifically on the human α5 chain, while the β1 chain can be of either human or mouse origin, indicating strict specificity for the α5β1 heterodimer (Bukowski et al., 2009, DOI: 10.1007/978-1-59745-332-5). In clinical testing, weekly 15 mg/kg IV dosing achieved trough serum levels >150 μg/mL, with 2-3x accumulation by Day 50, detectable antibody in ascites, reduction in circulating endothelial progenitor cells, and a favorable safety profile. The use of this antibody in IHC-P was demostrated (Bell McGuinn et al., 2011, PMID: 21276608). Clone F200, a Fab derivative of M200, is available upon request.

Characteristics: NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Purification: Protein A affinity purified

Purity: > 98 % as determined by SDS-PAGE

Endotoxin Level: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: Heterodimeric alpha5beta1Fc fusion protein

Isotype: IgG4, kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

OriginalSpeciesName: Human

OriginalFormat: IgG4

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details

Target: ITGA5 (Volociximab Biosimilar)

Target Type: Biosimilar

Background: Fibronectin receptor, CD49 antigen-like family member E, Integrin alpha-F, VLA-5, CD49e.

UniProt: P08648